Celebrity Event Hosted in Mumbai, India 

TORRANCE, Calif., Dec. 19, 2022 /PRNewswire/ — Emmaus Life Sciences, Inc. (OTCQX: EMMA), introduced at present that Dr. Yutaka Niihara, Chairman and Chief Executive Officer of the corporate, was feted at an occasion held on December 16, 2022 on the World Trade Center in Mumbai, India by the Minister of State of India, Arun Halder, in recognition of Dr. Niihara’s work in creating Endari® to deal with sickle cell illness (SCD). The occasion was hosted by Dr. Aviti Govatikar, a medical physician and former Mrs. World.

It is reported in India that over 20 million folks in that nation endure from SCD, a genetic dysfunction affecting people of African descent and different ethnic teams.  Underprivileged tribal communities in India are disproportionately affected by SCD due to a scarcity of remedies and sources.

Endari® is authorized within the U.S. and several other Gulf Cooperation Council nations to scale back the acute issues of sickle cell illness in grownup and pediatric sufferers 5 years of age and older. Endari® can also be out there on an early-access foundation within the Kingdom of Saudi Arabia and several other European Union nations however will not be but out there in India.

Dr. Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus, commented “We are grateful and humbled by the recent acknowledgement by the Indian Ministry of State and look forward to discussions with national and local officials in the country to make Endari available to SCD patients there.”

George Sekulich, Senior Vice President of Global Commercialization of Emmaus, added “India represents a large, unserved market and we intend to look for possible approaches to reach SCD patients there.”

About Emmaus Life Sciences

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical firm engaged within the discovery, growth, advertising and sale of progressive remedies and therapies, together with these within the uncommon and orphan illness classes.  For extra data, please go to www.emmausmedical.com.

About Endari® (prescription grade L-glutamine oral powder)

Indication – Endari® is indicated to scale back the acute issues of sickle cell illness in grownup and pediatric sufferers 5 years of age and older.

Important Safety Information

The most typical antagonistic reactions (incidence >10 %) in scientific research had been constipation, nausea, headache, belly ache, cough, ache in extremities, again ache, and chest ache.

Adverse reactions resulting in therapy discontinuation included one case every of hypersplenism, belly ache, dyspepsia, burning sensation, and scorching flash.

The security and efficacy of Endari® in pediatric sufferers with sickle cell illness youthful than 5 years of age has not been established.

For extra data, please see full Prescribing Information of Endari® at: www.ENDARIrx.com/PI.

About Sickle Cell Disease

There are roughly 100,000 folks residing with sickle cell illness (SCD) in the United States and thousands and thousands extra globally. The sickle gene is present in each ethnic group, not simply amongst these of African descent; and in the United States an estimated 1-in-365 African Americans and 1-in-16,300 Hispanic Americans are born with SCD.¹ The genetic mutation liable for SCD causes a person’s crimson blood cells to distort right into a “C” or a sickle form, lowering their means to move oxygen all through the physique. These sickled crimson blood cells break down quickly, change into very sticky, and develop a propensity to clump collectively, which causes them to change into caught and trigger injury inside blood vessels. The result’s lowered blood circulate to distal organs, which results in bodily signs of incapacitating ache, tissue and organ injury, and early demise.²

¹Source: Data & Statistics on Sickle Cell Disease – National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, December 2020.
²Source: Committee on Addressing Sickle Cell Disease – A Strategic Plan and Blueprint for Action — National Academy of Sciences Press, 2020.

Forward-looking Statements

This press launch accommodates forward-looking statements made pursuant to the secure harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, together with statements concerning potential entry to the Indian marketplace for Endari. These forward-looking statements are topic to quite a few assumptions, dangers and uncertainties which change over time, together with the chance of doing enterprise in India and different international markets and uncertainties associated to Emmaus’ working capital and talent to hold on its present operations and acquire wanted financing and different elements beforehand disclosed within the firm’s reviews filed with the Securities and Exchange Commission, and precise outcomes could differ materially.  Such forward-looking statements communicate solely as of the date they’re made, and Emmaus assumes no obligation to replace them, besides as could also be required by regulation. 

Company Contact:
Emmaus Life Sciences, Inc.
Willis Lee
Chief Operating Officer
(310) 214-0065, Ext. 1130
[email protected]

SOURCE Emmaus Life Sciences, Inc.